Dr. McKearn joined RiverVest in April 2008 as a Venture Partner and became a Managing Director in April 2011. He has over 25 years of experience as a successful “drug hunter and developer” in both large and small biopharma, including a decade in small-cap and venture-backed companies. John serves on the board of Otonomy Inc., Lumena Pharmaceuticals, Inc., Allakos and ZS Pharma, all RiverVest Fund II portfolio companies. Prior to joining RiverVest, he was president and CEO of Kalypsys, Inc., and has served on the boards of IDM Pharma, Inc. (acquired by Takeda), Epimmune and Keel Pharmaceuticals, Inc. John holds more than 50 patents and numerous patent applications, primarily in the areas of cancer treatment and inflammatory disease. John worked as a scientist with Searle / Pharmacia, from 1987-2003, including head of discovery research from 1997-2003. Through his efforts, John helped establish the groundwork for new studies that led to the commercialization of several major products, including DayPro, Arthrotec, and most notably, Celebrex, one of the leading pharmaceuticals to treat arthritis. Prior to 1987, John was a senior scientist at E.I. DuPont de Nemours and Company; a member of the Basel Institute for Immunology in Basel, Switzerland; and a research associate in the Department of Microbiology and Immunology at Washington University in St. Louis. Additionally, he has co-authored more than 70 published, peer-reviewed scientific papers. John completed his Ph.D. in immunology from the University of Chicago and his B.S. in biology from Northern Illinois University.
John McKearn, Ph.D., Chairman
John Donovan, President & CEO
Mr. Donovan has served as President and CEO of Tioma since joining the company in 2016. Mr. Donovan has more than two decades of industry experience, first as an investment banker and then as a member of senior leadership within several biotechnology companies. Prior to joining Tioma, Mr. Donovan was a co-founder of Alios BioPharma and served as its Chief Business Officer and Chief Financial Officer from January 2011 through its acquisition by Johnson & Johnson (November 2014) and ending in December of 2015. Prior to joining Alios, Mr. Donovan was Chief Financial Officer at CoMentis, a privately held biotechnology company. Previously, Mr. Donovan served as head of Strategic Planning & Corporate Communications at InterMune, a publicly traded biotechnology company (subsequently acquired by Roche), and he began his career as a corporate investment banker, first at Vector Securities International, a boutique life sciences investment bank, then at Banc of America Securities, a global, full-service investment bank. He received his Bachelors of Business Administration from the University of Notre Dame.
Ms. Carroll joined SR One in 2011 with a background in biotech partnering and commercial development. Prior to SR One, Jill was responsible for Corporate Development at Dynavax Technologies, where she was involved in multiple pharma partnering deals as well as substantial private and public financings. Previously, Jill was a consultant specializing in healthcare at Clearview Projects and Mercer Management Consulting. Jill received her B.S. in Chemistry from Duke University, and her M.S. in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University.
Peter Moldt, Ph.D.
Dr. Moldt joined Novo A/S in 2009. He is a member of the Board of Directors of Cardeas Inc, and was a board member of Cytochroma Inc., HemoFocus ApS and Neurokey A/S. In 2004, Dr. Moldt co-founded Curalogic A/S, served as CEO until 2009 and took the company public in 2006. From 2000 to 2004, he was Chief Operating Officer of 7TM Pharma A/S, which he also co-founded. Previously, he worked for 11 years with NeuroSearch A/S, where he was responsible for pre-clinical and clinical drug development. Dr. Moldt holds a Ph.D. in medicinal chemistry from the Royal Danish School of Pharmacy. He previously held a post-doctoral position with Yale University’s department of organic chemistry.
Ms. Nuechterlein joined F. Hoffmann-La Roche Ltd. in 2002 and currently serves as a deputy director and head of the Roche Venture Fund. Prior to that, Ms. Nuechterlein served as general counsel for SangStat, Inc. She currently serves on the board of directors for AveXis Inc and Lysosomal Therapeutics Inc and as an observer at Allakos and Epic Sciences. Ms. Nuechterlein holds a B.A. from Valparaiso University and a J.D. from University of Michigan.